Page 98 - The Flying Publisher Guide to Hepatitis C Treatment

98 | Hepatitis C Treatment

Selzner N, Renner EL, Selzner M, et al. Antiviral treatment of recurrent hepatitis
C after liver transplantation: predictors of response and long-term
outcome. Transplantation 2009;88:1214-21.
Shaheen AA, Myers RP. Systematic review and meta-analysis of the diagnostic
accuracy of fibrosis marker panels in patients with HIV/hepatitis C
coinfection. HIV Clin Trials 2008;9:43-51.
Shaheen AA, Wan AF, Myers RP. FibroTest and FibroScan for the prediction of
hepatitis C-related fibrosis: a systematic review of diagnostic test accuracy.
Am J Gastroenterol 2007;102:2589-600.
Sherman KE, Flamm SL, Afdhal NH, et al. Telaprevir in combination with
peginterferon alfa2a and ribavirin for 24 or 48 weeks in treatment-naïve
genotype 1 HCV patients who achieved an extended rapid viral response:
Final results of phase 3 ILLUMINATE Study. Hepatology 2010;52:401A.
Shiffman ML, Suter F, Bacon BR, et al. Peginterferon alfa-2a and ribavirin for 16
or 24 weeks in HCV genotype 2 or 3. N Engl J Med 2007;357:2609-17.
Sjogren MH, Sjogren R, Holtzmuller K, et al. Interferon alfacon-1 and ribavirin
versus interferon alpha-2b and ribavirin in the treatment of chronic
hepatitis C. Dig Dis Sci 2005;50:727-32.
Sommereyns C, Paul S, Staeheli P, Michiels T. IFN-lambda (IFN-lambda) is
expressed in a tissue-dependent fashion and primarily acts on epithelial
cells in vivo. PLoS Pathog 2008;14;4:e1000017.
Soriano V, Peters MG, Zeuzem S. New therapies for hepatitis C virus infection.
Clin Infect Dis 2009;48:313-20.
Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive
index to predict significant fibrosis in patients with HIV/HCV coinfection.
Hepatology 2006;43:1317-25.
Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management and
treatment of hepatitis C. Hepatology 2004;39:1147-71.
Sugawara Y, Tamura S, Kokudo N. Antiviral Treatment for Hepatitis C Virus
Infection after Liver Transplantation. Hepat Res Treat 2010;2010:475746.
Sulkowski M, Shiffman ML, Afdhal N, et al. Decline in hemoglobin is associated
with sustained virologic response (SVR) among HCV genotype 1-infected
persons treated with peginterferon (PEG)/ribavirin (RBV): Analysis from
the IDEAL study. J Hepatol 2009;50(Suppl 1):S51.
Sulkowski MS, Cooper C, Hunyady B, et al. Management of adverse effects of Peg-
IFN and ribavirin therapy for hepatitis C. Nat Rev Gastroenterol Hepatol
2011;8:212-23.
Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to
chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet
2009;41:1100-4.
Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with
response to pegylated interferon-alpha and ribavirin therapy for chronic
hepatitis C. Nat Genet 2009;41:1105-9.
Tanaka Y, Nishida N, Sugiyama M, Tokunaga K, Mizokami M. Lambda-Interferons
and the single nucleotide polymorphisms: A milestone to tailor-made
therapy for chronic hepatitis C. Hepatol Res 2010;40:449-60.
Terrault N. Hepatitis C therapy before and after liver transplantation. Liver
Transpl 2008;14:S58-66.